Julie Lisano

585 total citations
16 papers, 255 citations indexed

About

Julie Lisano is a scholar working on Pathology and Forensic Medicine, Oncology and Dermatology. According to data from OpenAlex, Julie Lisano has authored 16 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 11 papers in Oncology and 9 papers in Dermatology. Recurrent topics in Julie Lisano's work include Lymphoma Diagnosis and Treatment (14 papers), Cutaneous lymphoproliferative disorders research (9 papers) and CAR-T cell therapy research (7 papers). Julie Lisano is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Cutaneous lymphoproliferative disorders research (9 papers) and CAR-T cell therapy research (7 papers). Julie Lisano collaborates with scholars based in United States, Canada and Italy. Julie Lisano's co-authors include Muneer H. Abidi, Veronika Bachanová, Auayporn Nademanee, Jerzy Hołowiecki, Craig H. Moskowitz, Patrick J. Stiff, Edward Agura, Anna Sureda, John Sweetenham and Simonetta Viviani and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Julie Lisano

14 papers receiving 252 citations

Peers

Julie Lisano

PFM

ONCOL

NEURO

GENET

DERMA

Emanuela Anna Pesce Italy

Andrea Meinhardt Germany

Youngil Koh South Korea

Cristina Becchimanzi Italy

H. Tilly France

M. Dreyling Germany

Marion Fournier France

J.J. Luan France

Marianna Sassone Italy

Mitul Gandhi United States

Emanuela Anna Pesce Italy

Julie Lisano

257 ×1.3

PFM

169 ×1.0

ONCOL

42 ×0.5

NEURO

66 ×1.5

GENET

63 ×1.6

DERMA

Citations per year, relative to Julie Lisano Julie Lisano (= 1×) peers Emanuela Anna Pesce

Countries citing papers authored by Julie Lisano

Since Specialization

Citations

This map shows the geographic impact of Julie Lisano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Lisano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Lisano more than expected).

Fields of papers citing papers by Julie Lisano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Lisano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Lisano. The network helps show where Julie Lisano may publish in the future.

Co-authorship network of co-authors of Julie Lisano

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Lisano. A scholar is included among the top collaborators of Julie Lisano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Lisano. Julie Lisano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Zinzani, Pier Luigi, Gilles Salles, Alison J. Moskowitz, et al.. (2024). Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Blood Advances. 8(10). 2400–2404. 4 indexed citations

Santoro, Armando, Alison J. Moskowitz, Silvia Ferrari, et al.. (2023). Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma. Blood. 141(22). 2780–2783. 7 indexed citations

Zinzani, Pier Luigi, Armando Santoro, Giuseppe Gritti, et al.. (2023). Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up. Blood Advances. 7(18). 5272–5280. 18 indexed citations

Savage, Kerry J., et al.. (2023). Cost-Effectiveness of Brentuximab Vedotin Versus Physician’s Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada. Advances in Therapy. 40(5). 2326–2338.

Burke, John M., et al.. (2023). Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy. The Oncologist. 28(6). 520–530. 1 indexed citations

Harker‐Murray, Paul, Christine Mauz‐Körholz, Thierry Leblanc, et al.. (2022). Nivolumab, Brentuximab Vedotin, +/- Bendamustine For R/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults. Blood. 141(17). 2075–2084. 17 indexed citations

Lisano, Julie, et al.. (2022). Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada. Journal of Medical Economics. 25(1). 324–333. 2 indexed citations

Jagadeesh, Deepa, Steve Horwitz, Nancy L. Bartlett, et al.. (2022). Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. The Oncologist. 27(10). 864–873. 28 indexed citations

Petrilla, Allison, et al.. (2020). Health Care Resource Utilization and Costs Among Medicare Beneficiaries Newly Diagnosed With Peripheral T-cell Lymphoma: A Retrospective Claims Analysis. Clinical Lymphoma Myeloma & Leukemia. 21(1). e1–e9. 3 indexed citations

10.

Phillips, Tycel, Kristina Yu-Isenberg, Andy Surinach, et al.. (2020). Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching. Blood. 136(Supplement 1). 3–4. 2 indexed citations

11.

Burke, John M., Kristina Yu-Isenberg, Michelle A. Fanale, et al.. (2020). Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching. Blood. 136(Supplement 1). 18–19.

12.

Ahmed, Sairah, et al.. (2019). A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or Other CD30-Expressing PTCL. Blood. 134(Supplement_1). 4054–4054. 1 indexed citations

13.

Scarisbrick, Julia, Sarah McCue Horwitz, H. Miles Prince, et al.. (2019). Brentuximab vedotin (BV) versus physician’s choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides [MF] or primary cutaneous anaplastic large cell lymphoma [pcALCL]): final time to next therapy (TTNT) results from the phase 3 ALCANZA study. European Journal of Cancer. 119. S31–S31. 1 indexed citations

14.

Moskowitz, Craig H., Jan Walewski, Auayporn Nademanee, et al.. (2018). Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 132(25). 2639–2642. 156 indexed citations

15.

Díaz-Padilla, Iván, Lillian L. Siu, A.R. Abdul Razak, et al.. (2012). A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. British Journal of Cancer. 107(4). 604–611. 10 indexed citations

16.

Chen, Hongbin, Manuel Modiano, Joel W. Neal, et al.. (2012). A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 30(15_suppl). 7541–7541. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact